Selective Upregulation of Cardiac Endothelin System in Patients With Ischemic but Not Idiopathic Dilated Cardiomyopathy.
Endothelin-1 System in the Human Failing Heart by Neri Serneri, Gian Gastone et al.
Selective Upregulation of Cardiac Endothelin System in
Patients With Ischemic but Not Idiopathic
Dilated Cardiomyopathy
Endothelin-1 System in the Human Failing Heart
Gian Gastone Neri Serneri, Ilaria Cecioni, Simone Vanni, Rita Paniccia, Brunella Bandinelli,
Annamaria Vetere, Xiao Janming, Iacopo Bertolozzi, Maria Boddi, Gian Franco Lisi,
Guido Sani, Pietro Amedeo Modesti
Abstract—Only scarce information is available on the activity and modifications of the cardiac endothelin (ET)–1 system
in heart failure due to ischemic (ICM) or idiopathic dilated (DCM) cardiomyopathy. The activity of the ET-1 system
was investigated by measuring cardiac ET-1 and big ET-1 formation and quantifying cardiac mRNA for prepro–ET-1
(ppET-1), ET-converting enzyme-1, and ETA and ETB receptors both in myocardium and in isolated myocytes using
Northern blot, reverse transcription–polymerase chain reaction, and in situ hybridization in 22 patients with DCM and
20 with ICM who underwent cardiac transplantation and in 7 potential heart transplant donors (nonfailing hearts).
Notwithstanding a similar increase of plasma ET-1 in the 2 groups, cardiac ET formation, mRNA levels for ppET-1,
and ETA and ETB receptors were higher on both the myocardium and isolated myocytes from ICM than on those from
DCM hearts (P,0.001 for all). ppET-1 and ET-converting enzyme-1 mRNAs were expressed on myocytes and
endothelial and interstitial cells in ICM, whereas in DCM and nonfailing hearts they were mainly expressed on
nonmyocyte cells. In both ICM and DCM, the ETA mRNA signal was expressed on both myocytes and nonmyocyte
cells, whereas ETB mRNA was almost exclusively localized on nonmyocyte cells. ETA- and ETB-specific receptor
binding was increased on both myocytes and cardiac membranes, showing a positive correlation with left ventricular
ejection fraction in ICM (r50.78 and 0.70) but not in DCM patients. The present results show that human ventricular
myocytes express all of the components of the ET-1 system, which is selectively upregulated in ICM patients and
appears to be functionally important in the maintenance of cardiac function. (Circ Res. 2000;86:377-385.)
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Endothelin (ET)-1 is a multifunctional peptide that exertspleiotropic activities, including arterial and venous con-
striction, direct positive inotropic and chronotropic effects on
isolated heart, and growth effects on vascular smooth muscle
cells, fibroblasts, and isolated cardiomyocytes.1 Prepro–ET-1
(ppET-1) mRNA is expressed by both rat and human cardiac
myocytes and interstitial cells that synthesize and secrete
mature ET-1.2–4 The protease that catalyzes the conversion
(ET-converting enzyme, ECE) from the 38-residue inactive
intermediate big ET-1 to achieve ET-1 is expressed in the
endocardium and myocardium.5 The differing biological
activities of ET-1 appear to be mediated through 2 receptor
subtypes (ETA and ETB),6 which are both present in the
human myocardium and that of other species.7 Thus, a
complete ET-1 system is represented in human myocardium.
Cardiac ppET-1 mRNA expression and ET-1 synthesis
have been found to be increased in experimental hypertrophy
by pressure overload8–10 and in experimental models of
congestive heart failure (CHF),11–13 thus suggesting that the
cardiac ET-1 system may be involved in cardiac diseases.
There have been very few investigations of the cardiac
ET-1 system in human hypertrophy and heart failure. Expres-
sion of mRNA for ppET-1 and cardiac ET-1 formation have
been found to be increased in hypertrophy with parietal wall
stress ,90 kilodyne/cm2 because of aortic valve stenosis.4 In
situ hybridization has shown that ppET-1 mRNA is expressed
in myocytes and to a lesser degree also in vascular and
interstitial cells.4 Several studies have investigated cardiac
ET-1 receptors. In endomyocardial bioptic specimens from
patients with hypertrophic cardiomyopathy, mRNA expres-
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sion for ETA receptors was not different from controls.14 ET-1
receptor subtypes have recently been investigated in myocar-
dial homogenates of hearts from patients with end-stage
idiopathic dilated cardiomyopathy (DCM)15–17 or ischemic
cardiomyopathy (ICM),15 with conflicting results. Thus, de-
spite the great potential pathophysiological and clinical im-
plications of the cardiac ET-1 system,18 information about its
functional activity in heart failure is lacking. Two factors
might be critical in the study of the ET-1 system in this
setting, as follows: first, a separate analysis of ET-1 receptors
for myocytes and nonmyocyte myocardial cells, and second,
investigation of the cardiac ET-1 system in relation to the
etiology and severity of cardiac failure. The present study was
therefore designed to investigate the functional activity of the
cardiac ET-1 system in patients with DCM and ICM at
different stages of heart failure severity. To this end, cardiac
ET formation and receptor binding were evaluated and
mRNA levels of ppET-1, ECE-1, ETA, and ETB receptor
subtypes were quantified separately in isolated cardiomyo-
cytes and in homogenated hearts.
Materials and Methods
We investigated 42 patients with heart failure afflicted with DCM
(n522) or ICM (n520) who were scheduled to undergo cardiac
transplantation. Patients with arterial hypertension, a recent history
(,6 months) of myocardial infarction, or echocardiographic evi-
dence of valve or congenital heart disease were not considered for
the study. The control group was made up of 20 normotensive
patients with atypical chest pain in whom angiography and routine
diagnostic procedures did not reveal any abnormalities. Diagnosis of
DCM or ICM was based on clinical and echocardiographic exami-
nation, cardiac catheterization, and coronary angiography.
Myocardial ventricular tissue was collected from patients with
DCM and ICM during cardiac transplantation. Cardiac specimens
were also obtained from 7 donors with no histories or signs of heart
disease, whose hearts could not be transplanted because of surgical
reasons or blood group incompatibility (nonfailing [NF] hearts)
(Table 1). The protocol of this study complies with the principles of
the Helsinki declaration. All patients gave their informed, written
consent to participate and to have their heart and blood samples used
for the study. Echocardiographic and hemodynamic measurements
were performed prospectively, as previously described.4
The estimation of cardiac ET-1 formation was performed by
measuring the aorta-coronary sinus gradient of ET-1 and big ET-1
corrected for coronary flow and cardiac mass.4 Cardiomyocytes were
isolated and membrane suspension was prepared from a noninfarcted
portion of left ventricle free wall.19 Binding studies were performed
at equilibrium using selective ETA (BMS-182874, a gift of Bristol-
Myers-Squibb) or ETB (BQ-788) antagonists.19 mRNAs for ppET-1,
ECE-1, ETA, and ETB receptors, extracted with phenol-chloroform
from transmural myocardial specimens, were quantified with North-
ern blots, using a-32P–labeled gel-purified specific cDNA probes.
Levels of ppET-1, ECE-1, ETA, and ETB messengers were also
quantified both in the myocardium and in isolated myocytes by
reverse transcription–polymerase chain reaction (RT-PCR)4 using
specific primers.17 The densitometric ratio was calculated using
GAPDH as internal standard and expressed as the percentage of the
values obtained in NF hearts.4 The in situ hybridization procedure
was performed as previously described4 using specific cDNA
photobiotin-labeled (Vector) probes. Myocardial cell types were
identified by immunohistochemical methods using specific mono-
clonal antibodies. The average myocyte diameter was obtained by
measuring the short-axis length of 200 myocytes using a computer-
ized image-analysis system (Qwin, Leica).
Data are expressed as mean6SD. Comparisons between groups
were performed using 1-way ANOVA. For multivariate re-
evaluation of univariate correlations age, left ventricular end-diastol-
ic diameter index, left ventricular mass index, left ventricular
ejection fraction (LVEF), mean midwall velocity of circumferential
fiber shortening (Vcf), mean pulmonary artery pressure, pulmonary
capillary wedge pressure, average myocyte diameter, ET-1 and big
ET-1 cardiac production, and concentration of ET-1 in venous blood
were entered in a stepwise multiple regression analysis as indepen-
dent variables considering ETA and ETB receptor densities on
cardiomyocytes and membranes as dependent variables.
An expanded Materials and Methods section is available online at
http://www.circresaha.org.
Results
Plasma Assays of Cardiac ET-1 and Big
ET-1 Formation
The clinical characteristics of investigated subjects are re-
ported in Table 1.
TABLE 1. Main Echocardiographic and Hemodynamic Characteristics of
Subjects Investigated
Controls NF ICM DCM
NYHA class, III/IV z z z z z z 10/10 10/12
Age, y 58612 4465* 5966 56611
Sex, M/F 16/4 5/2 15/5 14/8
Body surface area, m2 1.8760.17 1.8660.18 1.8560.17 1.8360.26
LVEDDI, mm/m2 26.762.3 26.463.1 39.164.5* 44.166.7*†
LVMI, g/m2 107615 104618 213635* 266649*†
Ejection fraction, % 6364.5 6163.9 22.266.5* 1967.5*
Vcf, s21 1.1660.17 1.0960.23 0.4860.19* 0.4660.16*
Cardiac index, L/m23min21 2.9660.36 z z z 2.0460.45* 2.0360.40*
MPAP, mm Hg 15.262.3 z z z 32.3610.1* 33.7613.6*
PCWP, mm Hg 5.761.8 z z z 21.667.8* 21.669.3*
NYHA indicates New York Heart Association; LVEDDI, left ventricular end diastolic diameter index;
LVMI, left ventricular mass index; Vcf, mean midwall velocity of circumferential fiber shortening;
MPAP, mean pulmonary artery pressure; and PCWP, pulmonary capillary wedge pressure.
*P,0.01 vs controls; †P,0.01 vs ICM.
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ET-1 and big ET-1 plasma concentrations in peripheral
veins of ICM (3.161 and 15.263.3 pg/mL) and DCM
patients (2.860.9 and 17.264.1 pg/mL) were higher than in
controls (0.7960.4 and 4.761.6 pg/mL, P,0.001 for both),
with no significant differences between the 2 patient groups.
The mean aorta-coronary sinus concentration gradient of
ET-1 was not significantly different among the 3 groups.
Conversely, the concentration gradient of big ET-1 was
significantly higher in ICM (1.761.1 pg/mL, P,0.001) than
in DCM patients (21.461.8 pg/mL, P,0.001) or controls
(20.0460.23 pg/mL) (Figure 1A). The mean highest con-
centration gradient of big ET-1 was found in ICM and the
lowest in DCM patients, as well as the amount of big ET-1
formed per minute per gram of tissue (Figure 1B).
Radioligand Binding Studies
The density of ET-1 binding sites (Bmax) on myocytes isolated
from the left ventricle of NF hearts was 4266 fmol/mg
protein with 86% of ETA subtype (Table 2). Cardiac mem-
branes from NF hearts had an ET-1 binding site density (Bmax)
of 195625 fmol/mg with balanced proportions of ETA (63%)
and ETB (37%) (Table 2 and Figure 2A).
The density of ET-1 binding sites on myocytes was
significantly higher in ICM than DCM or NF hearts (Table 2).
Both ETA and ETB subtypes were increased in the same
proportion (145% and 150%, respectively) (Figure 2B). The
affinities of both subtypes were not significantly different
among the various groups (Table 2).
Membranes from ICM hearts showed significantly higher
binding site density than DCM (P,0.01) or NF (P,0.01)
hearts (Table 2) without any differences in the affinity with a
proportional increase of both ETA (162%, P,0.01) and ETB
(159%, P,0.01) (Table 2). The individual data of the
receptor densities are shown in Figure 2B.
Multivariate stepwise analysis revealed that ETA and ETB
receptor density on both myocytes and membranes from ICM
hearts was positively correlated with LVEF, whereas in DCM
hearts only ETB receptors demonstrated this positive correla-
tion (Table 3 and Figure 2C). ETA receptor density was
positively correlated with myocyte diameter in both ICM
(r50.80, P,0.01) and DCM (r50.66, P,0.01) hearts. No
correlation was found among ETA and ETB myocyte or
membrane receptor density and plasma concentration or
cardiac production of ET-1 and big ET-1.
Quantification of ppET-1, ECE-1, ETA, and ETB
mRNA Levels in the Myocardium and in
Isolated Cardiomyocytes
RT-PCR revealed that ppET-1, ECE-1, ETA, and ETB recep-
tor genes were expressed on myocytes isolated from all the
ventricles. Levels of mRNA for ppET-1, ECE-1, ETA, and
ETB receptors were significantly increased in myocytes from
ICM hearts (P,0.001 versus NF hearts for all) but were not
in myocytes from DCM hearts. No significant differences
were found between DCM and NF hearts (Figure 3A).
RT-PCR performed on homogenated hearts showed a
lower ETA/ETB mRNA ratio than in isolated myocytes, with
an increased expression of both ETA and ETB mRNAs in ICM
hearts (Figure 3A). mRNA for ppET-1 was also increased in
ICM hearts, whereas no differences were found for ECE-1
mRNA expression in comparison with DCM and NF hearts
(Figure 3A). Northern blots performed in myocardial samples
confirmed the increased expression of mRNA for ppET-1,
ETA, and ETB in ICM as compared with DCM and NF hearts
(Figure 3B).
Figure 1. A, Big ET-1 concentrations in aorta (Ao) and coronary
sinus (CS) blood in controls (C), and in ICM or DCM patients. B,
Big ET-1 (F) and ET-1 (E) cardiac formation in controls (C) and
in patients with ICM and DCM. Statistical significance in ET car-
diac generation in comparison with controls is reported at top of
columns. *P,0.05 vs controls in multiple-comparison test.
TABLE 2. Characterization of ET Receptors on Cardiomyocytes
and Cardiac Membranes
NF ICM DCM
Cardiomyocytes
Bmax Total, fmol/mg 4266 61610* 4868
Bmax ETA, fmol/mg 3665 5368* 4167
Bmax ETB, fmol/mg 661 962* 762
ETA;ETB 86;14 85;15 86;14
Kd ET-1, nmol/L 0.3260.03 0.3360.06 0.3160.05
Kd BMS182874(ETA), nmol/L 74629 83645 55612
Kd BQ788(ETB), nmol/L 0.6060.19 0.6560.08 0.7060.07
Cardiac membranes
Bmax Total, fmol/mg 195625 318672* 199637
Bmax ETA, fmol/mg 123618 207650* 131632
Bmax ETB, fmol/mg 72610 111627* 67617
ETA;ETB 63;37 65;35 66;34
Kd ET-1, nmol/L 0.3260.03 0.3560.07 0.3560.06
Kd BMS182874(ETA), nmol/L 57628 77622 52626
Kd BQ788(ETB), nmol/L 0.5060.08 0.3260.07 0.4560.07
*P,0.01 vs controls and DCM.
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In Situ Hybridization Studies
The average myocyte diameter was larger in ICM
(20.161.8 mm) than in DCM (17.260.9 mm, P,0.001) and
NF (15.261.4 mm, P,0.001) hearts. Negative and positive
controls for hybridization showed that the hybridization
signal was specific for mRNA, and mRNA in the biopsies
was intact (Figure 4A and 4B).
In NF (Figure 4C and 4D) and DCM (Figure 4G and 4H)
hearts, ppET-1 and ECE-1 mRNAs were mainly expressed on
the interstitial and endothelial cells, whereas in ICM speci-
mens a positive signal was also present in myocytes (Figures
4E and 4F). In NF hearts, ETA receptor mRNA was expressed
on both myocyte and nonmyocyte cells (Figure 5A), whereas
ETB receptors were almost exclusively localized on nonmyo-
cyte cells (Figure 5B). In ICM specimens, mRNA both for
ETA (Figure 5C) and ETB (Figure 5D) subtypes had the same
localization as observed in DCM specimens (Figure 5E and
5F) and NF hearts. The intensity of the signal was higher in
ICM specimens than in the other groups.
Discussion
The present study establishes the following for the first time
in humans: (1) the presence, distribution, and characterization
of ET-1 receptor subtypes in ventricular myocytes from NF
hearts; (2) the different pattern of ET-1 receptors on myo-
cytes and ventricular membranes in ICM versus DCM; and
(3) the selective activation of the cardiac ET-1 system in ICM
and its changes in relation to the progressive worsening of
heart failure.
Myocyte ET-1 Subtype Receptors
Binding studies and densitometric analysis for mRNA indi-
cated that both ETA and ETB receptors are represented in
ventricular myocytes from NF hearts, with a marked predom-
inance of ETA (86% versus 14%). The absolute density of
ET-1 receptors was higher in membranes than in myocytes,
with a more balanced proportion between ETA and ETB (63%
versus 37%). The different ratio of ETA and ETB receptors in
membranes and isolated myocytes may point to different
functions of the 2 receptor subtypes. There is evidence that
ETA receptors mediate the positive inotropic and growth-
promoting effects of ET-1.16,20,21 The close relationship found
in the present study between myocyte ETA receptor density
and myocyte diameter corroborates this role of ETA.
The function of ETB receptors is not yet completely clear.
Several studies have suggested that ETB receptors may act as
clearance receptors for ET-1,22 and the observation that ET-1
binding to ETB receptors is less stable than its binding to ETA
receptors19 supports the above hypothesis. Because the total
density of ETB receptors is higher in ventricular membranes
than in myocytes, it may be speculated that ETB receptors
may contribute to preventing excessive ET-1 myocardial
concentrations.
The modifications of ventricular ET-1 binding sites occur-
ring in CHF, particularly in DCMs, have been studied on
ventricular homogenates. The different densities of ET-1
binding sites and the different proportion between ETA and
ETB receptors on myocytes versus ventricular membranes
may be the cause of the discrepancies among the various
studies.15–17 Indeed, the densities of ET-1 binding sites in
membranes from ICM and DCM hearts have not been found
to differ significantly from those in NF hearts.15 Other studies
performed in DCM hearts have reported either increased ETA
density and ETB downregulation without any significant
changes in the total density,17 or enhanced total density due to
ETA increase without any modifications of ETB receptors.16
The separate analyses for myocytes and membranes, as
performed in the present study, demonstrate that ET-1 bind-
ing sites are increased only in ICM hearts, with a proportional
Figure 2. A, Competition of 125I-labeled ET-1–specific binding to
isolated cardiomyocytes (left) and cardiac membranes (right) by
ET-1 (F), BMS-182874 (), and BQ-788 (). Points are
mean6SD of experiments performed in the 7 NF hearts. B, ETA
(F) and ETB (E) binding site density on isolated cardiomyocytes
(left) and cardiac membranes (right) of NF, ICM, and DCM
hearts. *P,0.05 vs NF hearts in multiple-comparison test. C,
Relationship of the density of ETA receptors on cardiomyocytes
with LVEF (ICM [F], r50.78, P,0.001; DCM [E], r50.10, NS),
mean Vcf (ICM, r50.72, P,0.001; DCM, r50.05, NS), and myo-
cyte diameter (ICM, r50.80, P,0.001; DCM, r50.66, P,0.001).
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increase in ETA and ETB receptors both on myocytes and
membranes and with changes correlated to LVEF.
Upregulation of Cardiac ET-1 System and Its
Functional Meaning
The increased density of ETA and ETB receptors on myocytes
and ventricular membranes and the overexpression of mRNA
for ppET-1 and ECE-1 on myocytes indicate an upregulation
of the cardiac ET-1 system in ICM patients, resulting in an
accelerated cardiac synthesis of ET-1, as shown also by the
increased big ET-1 aorta-coronary sinus gradient. The ab-
sence of an accompanying increase in the ET-1 aorta-coro-
nary sinus gradient does not contradict this statement, be-
cause it may be due to the increased ET-1 degradation, to the
enhanced binding of ET-1 to its receptors, or to both. Because
ET-1 degradation was not investigated, this hypothesis cannot
be excluded. However, the increased density of ETA and ETB
receptors both on myocytes and ventricular membranes sug-
gests an enhanced capture of ET-1 by binding sites rather than
an increase in ET-1 degradation. This mechanism would be
consistent with the increased ET-1 concentration in cardiac
tissue reported in failing myocardium15,23,24 and with the
finding that DCM patients, who showed neither enhanced
cardiac ET-1 formation by myocytes nor increased receptor
density, had instead a significantly lower coronary sinus
gradient for big ET-1 than controls. In these patients, whose
mRNA for ECE-1 was not significantly different from NF
hearts, the negative gradient for big ET-1 was associated with
an ET-1 gradient that did not differ from that of controls or
ICM patients, suggesting an increased conversion of plasma
big ET-1 to ET-1 during the transcardiac passage. Upregula-
tion of mRNA for ppET-1, increased peptide ET-1 level, and
enhanced ET-1 receptor density were found in the myocar-
dium from rats with the coronary artery ligation model of
CHF.25–28 Conversely, ventricular ET-1 receptor density and
myocyte ET-1 production in pigs with pacing-induced CHF
were not different from those in control pigs.12 The present
results are thus consistent with experimental observations and
emphasize the different pattern of the cardiac ET-1 system in
ICM versus DCM patients.
ET-1 binding sites on cultured myocytes are downregu-
lated by pretreatment with ET-1,29 and the level of ETB
receptor mRNA is downregulated by ET-1 through decreas-
ing the intracellular stability of mRNA molecules.30 In ICM
patients, ETA and ETB receptors on both myocytes and
membranes were not downregulated, despite the elevated
TABLE 3. Correlation Between ETA and ETB Receptors and Clinical,
Hemodynamic, and Neurohormonal Variables (Stepwise Regression Analysis)
ICM DCM
ETA r ETB r ETA r ETB r
Isolated cardiomyocytes
Age, y 0.24 0.16 20.16 20.15
Plasma ET-1, pg/mL 20.35 20.49 0.27 0.41
Cardiac ET-1 production, pg/min3g21 0.19 0.19 20.10 0.11
Cardiac big ET-1 production, pg/min3g21 0.60 0.67 20.19 0.23
Mean myocyte diameter, mm 0.80* 0.71 0.66* 0.31
LVMI, g/m2 20.22 20.19 0.25 0.04
LVEDDI, mm/m2 20.24 20.33 20.02* 20.35
MPAP, mm Hg 0.05 0.09 20.18 0.10
PCWP, mm Hg 20.16 0.03 20.27 20.22
LVEF, % 0.78* 0.84* 0.10 0.42*
Vcf, s21 0.72 0.22 0.05 0.32
Cardiac membranes
Age, y 0.12 0.13 20.13 0.12
Plasma ET-1, pg/mL 20.14 20.24 0.28 0.38
Cardiac ET-1 production, pg/min3g21 20.07 0.06 0.14 20.30
Cardiac big ET-1 production, pg/min3g21 0.62 0.58 0.07 0.15
LVMI, g/m2 20.32 20.27 0.63* 0.11
LVEDDI, mm/m2 20.68* 20.55 0.51 20.07
MPAP, mm Hg 0.09 20.01 20.04 20.10
PCWP, mm Hg 0.07 20.03 20.14 20.28
LVEF, % 0.70* 0.65* 20.02 0.54*
Vcf, s21 0.65 0.64 0.25 0.24
LVMI indicates left ventricular mass index; LVEDDI, left ventricular end-diastolic diameter index;
MPAP, mean pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; LVEF, left
ventricular ejection fraction; and Vcf, mean midwall velocity of circumferential fiber shortening.
*Independent variable at stepwise regression.
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ET-1 plasma levels. Only in patients with very low ejection
fraction was the receptor density in the range of that of NF
hearts. The precise mechanism determining the lack of ET-1
receptor downregulation is not clear. Cardiac ET-1 formation
may be induced by different stimuli, including mechanical
forces, hypoxia, and angiotensin II,31 which may be operating
in ICM patients and may also upregulate the ET-1 receptors.
Thus, it may be speculated that when the cardiac ET-1
synthesis is activated by locally acting stimuli, the local
mechanisms of regulation predominate over the downregula-
tion induced by plasma ET-1 levels. However, specially
designed studies are needed to investigate this issue.
The upregulation of the cardiac ET-1 system seems to be
important in the maintenance of the cardiac function in
ICM patients, as indicated by the positive correlation of
ETA receptor density with LVEF and Vcf and, conversely,
the negative correlation between ETA receptors and left
ventricular end-diastolic diameter index. The functional
importance of cardiac ET-1–system activation seems to be
confined to the normally functioning myocytes or to
providing short-term support to failing myocardium.13,32
The favorable activity of ET-1 on cardiac function does not
rule out the possibility that in the long term it may have
adverse effects, because it has been shown to depress
myocardial contractility and relaxation in pacing-induced
CHF regardless of its effect on arterial load.33 Experimen-
tal studies have shown that the elevation of plasma ET-1
concentration, obtained by infusion, dose-dependently de-
creases myocyte contractility in pigs with pacing-induced
CHF,12 and the long-term administration of various selec-
tive ETA antagonists in experimental models of CHF in
different animal species prevents the contractility depres-
sion on both isolated myocyte34 and left ventricle.34 –37
Although the ET-1 cardiac system was not upregulated in
DCM patients, both ET-1 and big ET-1 plasma concentra-
tions were similarly increased in ICM and DCM patients. The
similar increase in ET-1 plasma levels in ICM and DCM
patients, reported also in previous studies,23,38 reflects the
severity of heart failure,23 especially the increase in pulmo-
nary arterial pressure,38 and the endothelial dysfunction,39 but
not the type of cardiomyopathy.
Mechanisms of Cardiac ET-1 Activation
The present investigation extends current knowledge re-
garding the role of ET-1 in the pathophysiology of severe
heart failure. The widely different pattern of the ET-1
system in ICM and DCM patients is not attributable to
apparent clinical, echocardiographic, and hemodynamic
differences, because the 2 groups of patients did not differ
either for these parameters or for the drugs administered.
Thus, it is reasonable to conclude that heart failure is not
in itself responsible for cardiac ET-1 system activation,
which is probably instead due to the primary disease
underlying the heart failure. There is evidence that me-
chanical forces selectively induce cardiac growth factor
synthesis in relation to pressure or volume overload.4,40,41
Although ICM consists of a complex mixture of ischemia,
stress due to myocardial scar, and often a component of
volume overload,42 myocytes are substantially subjected to
stretch because of pressure overload, given that the resid-
ual healthy myocytes are forced to face a greater workload
to compensate for the loss of neighboring contractile
elements resulting from myocardial infarction and chronic
myocardial ischemia. Experimental and human pressure-
overload hypertrophy is associated with an increased ET-1
formation.4,8,9 In addition, in experimental severe heart
failure induced by coronary artery ligation, an increased
expression of ppET-1 mRNA was reported in nonischemic
myocardial areas.25,28 Hypoxia and acute experimental
ischemia have each been reported to induce ET-1 forma-
Figure 3. A, Expression of ppET-1,
ECE-1, ETA, ETB, and GAPDH in ventric-
ular cardiomyocytes and homogenated
hearts from NF, ICM, and DCM subjects;
representative RT-PCR experiments. Bar
graphs show changes in the densitomet-
ric GAPDH ratio (ppET-1, ECE-1, ETA,
and ETB/GAPDH). B, Northern blot anal-
ysis of mRNA expression for ppET-1,
ECE-1, ETA, ETB, and GAPDH in hearts
from NF and from ICM and DCM
patients. *P,0.05 vs NF hearts in
multiple-comparison test.
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tion in isolated myocytes43 or ventricular myocardium.44
However, ischemia does not seem to be a major mecha-
nism in the increased ET-1 formation in ICM patients,
because an ischemic component is present in the heart of
DCM patients45,46 and myocardial perfusion is impaired
both at rest and in response to vasodilating stimuli in DCM
patients.47 Therefore, pressure overload seems to be a
major mechanism of cardiac ET-1 system activation in
ICM.
The inciting factor of DCM is unknown, but this condition
is characterized by ventricular remodeling producing cham-
ber dilation with normal or decreased wall thickness. The
resulting eccentric hypertrophy45,48 suggests volume overload
as a prevalent hemodynamic mechanism. Patients with pre-
dominant volume-overload hypertrophy, like those with aor-
tic regurgitation, show no evidence of increased myocyte
ET-1 formation.4
Hence, although we cannot exclude other mechanisms,
including the incapacity of myocytes from DCM patients to
produce ET-1 in response to mechanical forces or cardiac and
humoral factors, the different type of hemodynamic overload
would seem to be the major mechanism responsible for the
different patterns of the cardiac ET-1 system in
cardiomyopathies.
In conclusion, the cardiac ET-1 system is selectively
upregulated in ICM patients, whereas it is not in DCM
Figure 4. In situ hybridization for
GAPDH mRNA (A) and plasmid vector
pBR322 mRNA (B) in NF hearts, and for
ppET-1 mRNA (C, E, and G) and ECE-1
mRNA (D, F, and H) in left ventricular
sections from NF (C and D), ICM (E and
F), and DCM (G and H) hearts (original
magnification, 3400). Positive mRNA
signal revealed by red-brown staining. In
NF hearts, positive signal for ppET-1 (C)
and ECE-1 (D) mRNAs is detectable
mainly in interstitial and endothelial cells.
In ICM hearts, both ppET-1 (E) and
ECE-1 (F) mRNAs are detectable also in
the perinuclear region of myocytes. In
DCM hearts, positive ppET-1 (G) and
ECE-1 (H) mRNA signals are detectable
both in myocytes and nonmyocytes to a
lesser extent than in ICM hearts.
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patients, and it appears to be functionally important for the
maintenance of cardiac function in the former.
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